Midregional pro-atrial natriuretic peptide (MR-proANP) is an excellent marker for diagnosing congestive heart failure or acute destabilized heart failure in short-of-breath patients. MR-proANP provides additional information especially in diagnostically challenging subgroups such as obesity, higher age or renal function to routinely used markers.
Midregional pro-adrenomedullin (MR-proADM) is a new diagnostic parameter for outcome prediction and estimation of severity of illness in patients presented to the emergency department and diagnosed with the following diseases:
- Acute myocardial infarction
- Acute destabilized heart failure
- Lower respiratory tract infections (also refer to Procalcitonin)
For more information, download “MR-proADM Optimize risk assessment, decision making and treatment processes“.
Copeptin (Vasopressin) is a new diagnostic parameter that – together with a Troponin test and other clinic findings – allow for the early rule out of acute myocardial infarction (AMI) in patients with chest pain. Patients negative for both markers can be directed towards the appropriate care pathway:
- At initial presentation
- Without serial blood sampling
- With a NPV (Negative predictive value) of 99.7%
Make the right decision on treatment and patient management!
Copeptin is also used to differentiate all forms of diabetes insipidus from primary polydipsia with an easy to use assay technology at highest sensitivity and stability.
For more information, download the product information brochure here: